JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B5611 DMH4
1 Citation

Summary: VEGFR-2 inhibitor

<20.02 mg/mL
B5835 AZD2932

Target: FLT3|VEGFR|PDGFR|c-Kit

Summary: inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit

Soluble in DMSO
B5864 Fruquintinib(HMPL-013)

Target: VEGFR

Summary: Potent and selective inhibitor of VEGFR 1, 2, 3

insoluble in H2O; insoluble in EtOH; ≥6.35 mg/mL
B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL
B6199 BFH772

Summary: VEGFR2 inhibitor

≥53.4 mg/mL
B7800 BAW2881 (NVP-BAW2881)

Summary: VEGFR inhibitor

≥42.4 mg/mL
C3342 MAZ51

Target: VEGFR

Summary: VEGFR3 antagonist

insoluble in EtOH; insoluble in H2O; ≥31.4 mg/mL
C3415 Tivozanib (hydrate)

Summary: VEGFR inhibitor, orally available

≤25 mg/mL
C3730 AAL-993

Summary: VEGF receptors inhibitor

≤1 mg/mL
C4603 VEGFR Tyrosine Kinase Inhibitor II
1 Citation

Summary: VEGFR inhibitor

≤25 mg/mL